Patent 11951121 was granted and assigned to Voyager Therapeutics on April, 2024 by the United States Patent and Trademark Office.
The present invention relates to small interfering RNA (siRNA) molecules against the HTT gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating Huntington's Disease (HD) using the siRNA molecules and AAV vectors.